Literature DB >> 24421492

Drug monographs: cabozantanib and omacetaxine.

Dominic A Solimando1, Kristin V Ho1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@aol.com; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24421492      PMCID： PMC3839469          DOI： 10.1310/hpj4805-373

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  17 in total

1.  Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.

Authors:  Yu-Feng Li; Zhi-Kui Deng; Heng-Bao Xuan; Jia-Bin Zhu; Bang-He Ding; Xiao-Ning Liu; Bao-An Chen
Journal:  Chin Med J (Engl)       Date:  2009-06-20       Impact factor: 2.628

2.  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Authors:  F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

3.  Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Authors:  Razelle Kurzrock; Steven I Sherman; Douglas W Ball; Arlene A Forastiere; Roger B Cohen; Ranee Mehra; David G Pfister; Ezra E W Cohen; Linda Janisch; Forlisa Nauling; David S Hong; Chaan S Ng; Lei Ye; Robert F Gagel; John Frye; Thomas Müller; Mark J Ratain; Ravi Salgia
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

4.  High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Jessica Yu; Xiao-Li Liu; Zhen Xiao; Hong-Qian Zhu
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

5.  Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.

Authors:  S O'Brien; H Kantarjian; M Keating; M Beran; C Koller; L E Robertson; J Hester; M B Rios; M Andreeff; M Talpaz
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

6.  Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.

Authors:  E J Feldman; K P Seiter; T Ahmed; P Baskind; Z A Arlin
Journal:  Leukemia       Date:  1996-01       Impact factor: 11.528

7.  Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.

Authors:  E Feldman; Z Arlin; T Ahmed; A Mittelman; C Puccio; H Chun; P Cook; P Baskind
Journal:  Leukemia       Date:  1992-11       Impact factor: 11.528

Review 8.  Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

9.  Phase I clinical investigation of homoharringtonine.

Authors:  S S Legha; M Keating; S Picket; J A Ajani; M Ewer; G P Bodey
Journal:  Cancer Treat Rep       Date:  1984-09

10.  A clinical trial of homoharringtonine in the treatment of advanced breast cancer.

Authors:  T P Zhao; G X Ding; H Y Gao; Z Z Shen; K Y Li
Journal:  Tumori       Date:  1986-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.